Breaching Barriers in Glioblastoma Targeted Drug Delivery


  • Gerardo Caruso Unit of Neurosurgery, Department of Biomedical and Dental Sciences and Morphofunctional Imaging, University of Messina, Messina, Italy
  • Aristide Nanni Unit of Neurosurgery, Department of Biomedical and Dental Sciences and Morphofunctional Imaging, University of Messina, Messina, Italy
  • Kumar Rajiv NIET, National Institute of Medical Science, New Delhi 110007, India and University of Delhi, New Delhi 110007, India
  • Tamara Ius Unit of Neurosurgery, Head-Neck and Neuroscience Department, University Hospital of Udine, Italy
  • Maria Caffo Unit of Neurosurgery, Department of Biomedical and Dental Sciences and Morphofunctional Imaging, University of Messina, Messina, Italy


Blood-Brain Barrier, Brain Tumors, Drug Delivery, Glioblastoma, Nanoparticles, Nanotechnologies, Target Therapy


Tailored nanocarriers have gained huge research focus for brain drug delivery, aimed at combating several neuro-oncological conditions, such as the glioblastoma. The progress of knowledge on the pathogenesis of glioblastoma has allowed identifying the major hurdles for efficient treatment, encompassing biological interfaces (blood-brain barrier and blood-brain tumor barrier), specificities of tumor microenvironment, as well as both bulk and glioma stem cell subpopulations. These findings provided new insights into the molecular basis of glioblastoma, being a strong driving force behind development of targeted nanomedicines in this area. Diversified nanoparticles have been designed to target glioblastoma surface markers, overexpressed receptors, aberrant genes and signaling pathways, in addition to contemplating barriers targeting strategies. Nanotechnologies claim important and unique features, including the versatility in promoting both passive and active drug targeting, making them excellent candidates for brain drug delivery and one of the most appealing to overcome the obstacles of the current glioblastoma treatment. In this short review, we will report the mechanisms of overcoming the blood-brain barrier as well as various studies relating to the applications of nanotechnologies as drug delivery carriers in glioblastoma treatment.


Louis DN, Perry A, Wesseling P, et al. The 2021 WHO classification of tumors of the central nervous system: a summary. Neuro Oncol 2021; 23: 1231-1251.

Weller M, van den Bent M, Tonn JC, et al. European Association for Neuro-Oncology (EANO) guideline on the diagnosis and treatment of adult astrocytic and oligodendroglial gliomas. Lancet Oncol 2017; 18: e315-e329.

Schucht P, Beck J, Abu-Isa J, et al. Gross total resection rates in contemporary glioblastoma surgery: results of an institutional protocol combining 5-aminolevulinic acid intraoperative fluorescence imaging and brain mapping. Neurosurgery 2012; 71: 927-936.

Caruso G, Marino D, Caffo M. Nanoparticles and CNS delivery of therapeutic agents in the treatment of primary brain tumors. J Analyt Oncol 2014; 3: 105-112.

Karim R, Palazzo C, Evrard B, Piel G. Nanocarriers for the treatment of glioblastoma multiforme: Current state of the art J Control Release 2016; 227: 23-37.

Steichen SD, Caldorera-Moor M, Peppas NA. A review of current nanoparticle and targeting moieties for the delivery of cancer therapeutics. Eur J Pharm Sci 2013; 48: 416-427.

Yu M, Yang Y, Zhu C, Guo S, Gan Y. Advances in the transepithelial transport of nanoparticles. Drug Discov Today 2016; 21: 1155-1161.

Pourgholi F, Hajivalili M, Farhad J, Kafil HS, Yousefi M. Nanoparticles: Novel vehicles in treatment of Glioblastoma. Biomed Pharmacother 2016; 77: 98-107.

Nguyen VH, Lee BJ. Protein corona: a new approach for nanomedicine design. Int J Nanomedicine 2017; 12: 3137-3151.

Jue TR, McDonald KL. The challenges associated with molecular targeted therapies for glioblastoma. J Neurooncol 2016; 127: 427-434.

Hendricks BK, Cohen-Gadol AA, Miller JC. Novel delivery methods bypassing the blood-brain and blood-tumor barriers. Neurosurg Focus 2015; 38: E10.

Peluffo H, Unzueta U, Negro-Demontel ML et al. BBB-targeting, protein-based nanomedicines for drug and nucleic acid delivery to the CNS. Biotechnol Adv 2015; 33: 277-287.

Woodworth GF, Dunn GP, Nance EA, Hanes J, Brem H. Emerging insights into barriers to effective brain tumor therapeutics. Front Oncol 2014; 4: 126.

Hoosain FG, Choonara YE, Tomar LK, et al. Bypassing P-glycoprotein drug efflux mechanisms: possible applications in pharmacoresistant schizophrenia therapy. BioMed Res Int 2015; 2015: 484963.

Van Tellingen O, Yetkin-Arik B, de Gooijer MC, et al. Overcoming the blood-brain tumor barrier for effective glioblastoma treatment. Drug Resist Updat 2015; 19: 1-12.

Batrakova EV, Kim MS. Using exosomes, naturally-equipped nanocarriers, for drug delivery. J Control Release 2015; 219: 396-405.

Lajoie JM, Shusta EV. Targeting receptor-mediated transport for delivery of biologics across the blood-brain barrier. Annu Rev Pharmacol Toxicol 2015; 55: 613-631.

Liu L, Wan W, Xia S, Kalionis B, Li Y. Dysfunctional Wnt/β-catenin signaling contributes to blood-brain barrier breakdown in Alzheimer's disease. Neurochem Int 2014; 75: 19-25.

Gao W, Zhang Y, Zhang Q, Zhang L. Nanoparticle-hydrogel: A hybrid biomaterial system for localized drug delivery. Ann Biomed Eng 2016; 44: 2049-2061.

Gillies RJ, Gatenby RA. Metabolism and its sequelae in cancer evolution and therapy. Cancer J 2015; 21: 88-96.

Aldea M, Florian IA, Kacso G, et al. Nanoparticles for targeting intratumoral hypoxia: Exploiting a potential weakness of glioblastoma. Pharm Res 2016; 33: 2059-2077.

Huang G. Glyconanoparticles-an update. Curr Med Chem 2013; 20: 782-788.

Qiao L, Liang N, Zhang J, et al. Advanced research on vasculogenic mimicry in cancer. J Cell Mol Med 2015; 19: 315-326.

Koukourakis MI, Nitrakas AG, Giatromanolaki A. Therapeutic interactions of autophagy with radiation and temozolomide in glioblastoma: evidence and issues to resolve. Br J Cancer 2016; 114: 485-496.

Auffinger B, Spencer D, Pytel P, Ahmed AU, Lesniak MS. The role of glioma stem cells in chemotherapy resistance and glioblastoma multiforme recurrence. Expert Rev Neurother 2015; 15: 741-752.

Jin T. Gradient sensing during chemotaxis. Curr Opin Cell Biol 2013; 25: 532-537.

Zhang F, Zhang L, Qi Y, Xu H. Mitochondrial cAMP signaling. Cell Mol Life Sci 2016; 73: 4577-4590.

Taylor JW Schiff D. Treatment considerations for MGMT-unmethylated glioblastoma. Curr Neurol Neurosci Rep 2015; 15: 507.

Wu W, Wu Z, Yu T, Jiang C, Kim W. Recent progress on magnetic iron oxide nanoparticles: synthesis, surface functional strategies and biomedical applications. Sci Technol Adv Mat 2015; 16: 023501.

Kinsella TJ. Coordination of DNA mismatch repair and base excision repair processing of chemotherapy and radiation damage for targeting resistant cancers. Clin Cancer Res 2009; 15: 1853-1859.

Begum R, Martin SA. Targeting mismatch repair defects: A novel strategy for personalized cancer treatment. DNA Repair (Amst) 2016; 38: 135-139.

Cui Y, Xu Q, Chow PK, Wang D, Wang C. Transferrin-conjugated magnetic silica PLGA nanoparticles loaded with doxorubicin and paclitaxel for brain glioma treatment. Biomaterials 2013; 34: 8511-8520.

Xin H, Sha X, Jiang X, et al. Anti-glioblastoma efficacy and safety of paclitaxel-loading Angiopep-conjugated dual targeting PEG-PCL nanoparticles. Biomaterials 2012; 33: 8167-8176.

Brioschi AM, Calderoni S, Pradotto LG, et al. Solid lipid nanoparticles carrying oligonucleotides inhibit vascular endothelial growth factor expression in rat glioma models. J Nanoneurosci 2009; 1: 65-74.

Grodzik M, Sawosz E, Wierzbicki M, et al. VEGF-dependent mechanism of anti-angiogenic action of diamond nanoparticles in glioblastoma multiforme tumor. NSTI-Nanotech 2012; 3: 6276-6279.

Abakumov MA, Nukolova NV, Sokolsky-Papkov M, et al. VEGF-targeted magnetic nanoparticles for MRI visualization of brain tumor. Nanomedicine 2015; 11: 825-833.

Yan H, Wang J, Yi P, et al. Imaging brain tumor by dendrimer-based optical/paramagnetic nanoprobe across the blood-brain barrier. Chem Commun 2011; 47: 8130-8132.

Ren Y, Kang CS, Yuan XB, et al. Co-delivery of as-miR-21 and 5-FU by poly(amidoamine) dendrimer attenuates human glioma cell growth in vitro. J Biomater Sci Polym Ed 2019; 21: 303-314.

Gaspar LE, Fisher BJ, MacDonald DR, et al. Supratentorial malignant glioma: patterns of recurrence and implications for external beam local treatment. Int J Radiat Oncol Biol Phys 1992; 24: 55-57.

Gajbhiye V, Jain NK. The treatment of Glioblastoma Xenografts by surfactant conjugated dendritic nanoconjugates. Biomaterials 2011; 32: 6213-6225.

Shi K, Zhou J, Zhang Q, et al. Arginine-glycine-aspartic acid-modified lipid-polymer hybrid nanoparticles for docetaxel delivery in glioblastoma multiforme. J Biomed Nanotechnol 2015; 11: 382-391.

Ganipineni LP, Ucakar B, Joudiou N, et al. Paclitaxel-loaded multifunctional nanoparticles for the targeted treatment of glioblastoma. J Drug Target 2019; 27: 614-623.

Kang T, Jiang M, Jiang D, et al. Enhancing glioblastoma-specific penetration by functionalization of nanoparticles with an iron-mimic peptide targeting transferrin/transferrin receptor complex. Mol Pharm 2015; 12: 2947-2961.

Householder KT, DiPerna DM, Chung EP, et al. Intravenous delivery of camptothecin-loaded PLGA nanoparticles for the treatment of intracranial glioma. Int J Pharm 2015; 479: 374-380.

Gaudin A, Song E, King AR, et al. PEGylated squalenoyl-gemcitabine nanoparticles for the treatment of glioblastoma. Biomaterials 2016; 105: 136-144.

King AR, Corso CD, Chen EM, et al. Local DNA repair inhibition for sustained radiosensitization of high-grade gliomas. Mol Cancer Ther 2017; 16: 1456-1469.

Zhang C, Xhao W, Liu L, et al. A nanostructure of functional targeting epirubicin liposomes dually modified with aminophenyl glucose and cyclic pentapeptide used for brain glioblastoma treatment. Oncotarget 2015; 6: 32681-32700.

Kaluzova M, Bouras A, Machaidze R, Hadjipanayis CG. Targeted therapy of glioblastoma stem-like cells and tumor non-stem cells using cetuximabconjugated iron-oxide nanoparticles. Oncotarget 2015; 6: 8788-8806.

Cohen ZR, Ramishetti S, Peshes-Yaloz N, et al. Localized RNAi therapeutics of chemoresistant grade IV glioma using hyaluronan-grafted lipid-based nanoparticles. ACS Nano 2015; 9: 1581-1591.

Danhier F, Messaoudi K, Lemaire L, Benoit JP, Lagarce F. Combined anti-Galectin-1 and anti-EGFR siRNA-loaded chitosan-lipid nanocapsules decrease temozolomide resistance in glioblastoma: in vivo evaluation. Int J Pharm 2015; 481: 154-161.

Erel-Akbaba G, Carvalho LA, Tian T, et al. Radiation-induced targeted nanoparticle-based gene delivery for brain tumor therapy. ACS Nano 2019; 13: 4028-4040.

Seo Y, Suh H, Bahal R, et al. Nanoparticle-mediated intratumoral inhibition of miR-21 for improved survival in glioblastoma. Biomaterials 2019; 201: 87-98.

Li Y, Hermanson DL, Moriarity BS, Kaufman DS. Human iPSC-derived natural killer cells engineered with chimeric antigen receptors enhance anti-tumor activity. Cell Stem Cell 2018; 23: 181-192.e5.

Safari H, Kelley WJ, Saito E, et al. Neutrophils preferentially phagocytose elongated particles-An opportunity for selective targeting in acute inflammatory diseases. Sci Adv 2020; 6: 1474.

Chang Y, Syahirah R, Wang X, et al. Engineering chimeric antigen receptor neutrophils from human pluripotent stem cells for targeted cancer immunotherapy. Cell Rep 2022; 40: 111128.

Wang D, Starr R, Chang W, et al. Chlorotoxin-directed CAR T cells for specific and effective targeting of glioblastoma. Sci Transl Med 2020; 12: 2672.

Lu G, Wang X, Li F, et al. Engineered biomimetic nanoparticles achieve targeted delivery and efficient metabolism-based synergistic therapy against glioblastoma. Nat Commun 2022; 13: 4214.

Caruso G, Caffo M, Alafaci C, et al. Could nanoparticle systems have a role in the treatment of cerebral gliomas? Nanomedicine 2011; 7: 744-752.




How to Cite

Caruso, G., Nanni, A., Rajiv, K., Ius, T., & Caffo, M. (2023). Breaching Barriers in Glioblastoma Targeted Drug Delivery. Journal of Analytical Oncology, 12, 84–94. Retrieved from




Most read articles by the same author(s)